The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer

2022 ◽  
Vol 141 ◽  
pp. 280-286
Author(s):  
Gamze Guney Eskiler ◽  
Asuman Deveci Özkan
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Toll Like Receptors ◽  
The Relationship

Significance of PDL1 positive in TNBC.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12557-e12557
Author(s):  
Seiichi Imanishi ◽  
Hirotaka Morishima ◽  
Naofumi Oda ◽  
Junichi Hasegawa
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Tumor ◽  
Positive Group ◽  
Biopsy Specimens ◽  
Positive Rate ◽  
Neo Adjuvant Chemotherapy ◽  
The Relationship ◽  
Worse Prognosis

e12557 Background: Atezolizumab was approved for PD-L1-positive advanced recurrent triple negative breast cancer. However, it is controversial about when and when to measure PD-L1. Here we retrospectively reaearched how PD-L1 positivity rates in biopsy, surgical, and recurrent specimens for triple-negative breast cancer (TNBC) treated with neo adjuvant chemotherapy (NAC). We also investigated the relationship between androgen receptor (AR) and PD-L1, and researched the significance of PD-L1 positivity on TNBC. Methods: 28 TNBC biopsy samples before NAC, 16 surgical specimens with residual tumor after NAC, and 5 cases reccurence specimens were obtained subjected to stain for PDL1 using the SP142 antibody. AR staining was also performed on biopsy specimens. PD-L1 score determination was performed according to the Ventana OptiView PD-L1 (SP142) inspection guide, and AR positive cuttoff was setted 1% or more. Results: The PD-L1 positivity rates of the biopsy samples were IC0: 46.4%, IC1: 25.0%, IC2: 21.4%, IC3: 7.1%, TC0: 28.6%, TC1: 28.6%, TC2: 42.9%, TC: 0%. In the surgical specimens after NAC, PD-L1 showed almost no change in IC ( P = 0.38), but the score significantly decreased in TC ( P < 0.001). The recurrence specimesn that could be collected were IC0: 60%, IC1: 20%, IC2: 20%, IC3: 0%, TC0: 60%, TC1: 20%, TC2: 20%. There were four AR-positive cases, one of which showed TC2, but the others were negative.In terms of prognosis, both the DFS and OS in the PD-L1 strongly positive group (IC≥2 and TC≥2) and other groups Poor in PD-L1 strongly positive group ( P < 0.01, P = 0.041, respectively). Conclusions: TC was affected by NAC, the score decreased markedly, and the positive rate at the site of recurrence also tended to decrease. The PD-L1 strong positive had a significantly worse prognosis than the others. It was suggested that PD-L1 immunostaining may be effective in predicting prognosis by considering TC as well as IC.

Landscape of Toll-like receptors expression in tumor microenvironment of Triple Negative Breast Cancer (TNBC): distinct roles of TLR4 and TLR8

Gene ◽  
2021 ◽  
pp. 145728
Author(s):  
Anirban Roychowdhury ◽  
Mayur Jondhale ◽  
Elveera Saldanha ◽  
Deblina Ghosh ◽  
Chinmay Kumar Panda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Microenvironment ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Toll Like Receptors

The relationship between body mass index, diabetes, and triple-negative breast cancer prognosis.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 1108-1108
Author(s):  
Jose Maria Pacheco ◽  
Sarah Tait ◽  
Feng Gao ◽  
Caroline Bumb ◽  
Matthew James Ellis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
The Relationship

scholarly journals Clinico-pathological relationship between androgen receptor (AR) and tumor infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC)

2021 ◽  
Author(s):  
Thanaa Helal ◽  
Joaira Bakkach ◽  
Hagar Elghazawy ◽  
Ahmed Aref ◽  
Mohamed Kelany ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Tumor Infiltrating Lymphocytes ◽  
Lymph Node Involvement ◽  
Node Involvement ◽  
Infiltrating Lymphocytes ◽  
The Relationship

Abstract Background Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with ill-defined therapeutic targets. Androgen receptor (AR) and tumor-infiltrating lymphocytes (TILs) had a prognostic and predictive value in TNBC. The relationship between AR, TILs and clinical behavior is still not fully understood. Methods Thirty-six TNBC patients were evaluated for AR (positive if ≥ 1% expression), CD3, CD4, CD8 and CD20 by immunohistochemistry. Stromal TILs were quantified following TILs Working Group recommendations. Lymphocyte-predominant breast cancer (LPBC) was defined as having stromal TILs ≥ 50%, whereas lymphocyte-deficient breast cancer (LDBC) was defined as < 50%. Results The mean age was 52.5 years and 27.8% were ≥ 60 years. Seven patients (21.2%) were AR+. All AR + cases were postmenopausal (≥ 50 years old). No statistical difference was found in median overall survival (OS) between AR- and AR + groups (31.5 vs. 25 months, p = 0.77). LPBC was 32.2%. Median TILs was 37.5% and 10% (p = 0.1) and median CD20 was 20% and 7.5% (p = 0.008) in AR- and AR+, respectively. Mean CD3 was 80.7% and 93.3% (p = 0.007) and CD8 was 75% and 80.8% (p = 0.41) in AR- and AR + respectively. All patients who were ≥ 60 years old expressed CD20. LDBC was found to be significantly higher in N + vs. N- patients (p = 0.03) with median TILs of 20% vs. 50% in N + vs. N-, respectively (p = 0.03). LDBC was associated with higher risk of lymph node involvement (OR = 6, 95% CI = 1.05–34.21, p = 0.04). Conclusions AR expression was evident in older age (≥ 50 years). Median CD20 was higher in AR- TNBC, while mean CD3 was higher in AR + tumors. LDBC was associated with higher risk of lymph node involvement. Larger studies are needed to focus on the clinical impact of the relation between AR and TILs in TNBC.

scholarly journals ERβ in Triple-Negative Breast Cancer: Emerging Concepts and Therapeutic Possibilities

Endocrines ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. 356-365
Author(s):  
Alessandra Monaco ◽  
Fabrizio Licitra ◽  
Martina Di Gisi ◽  
Giovanni Galasso ◽  
Marzia Di Donato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Estrogen Receptor Alpha ◽  
Triple Negative ◽  
Therapeutic Approaches ◽  
Therapeutic Implications ◽  
Mediated Effects ◽  
The Relationship ◽  
Tnbc Subtype

Despite the improvements in diagnostic and therapeutic approaches, breast cancer still remains one of the world’s leading causes of death among women. Particularly, triple negative breast cancer (TNBC) is characterized by aggressiveness, metastatic spreading, drug resistance and a very high percentage of death in patients. Nowadays, identification of new targets in TNBC appears very compelling. TNBC are considered negative for the estrogen receptor alpha (ERα) expression. Nevertheless, they often express ERβ and its variants. As such, this TNBC subtype still responds to estrogens. While the ERβ1 variant seems to act as a tumor-suppressor, the two variants ERβ2 and 5 exhibit pro-oncogenic activities in TNBC. Thus, ERβ1 activation might be used to limit the growth and spreading as well as to increase the drug sensitivity of TNBC. In contrast, the pro-oncogenic properties of ERβ2 and ERβ5 suggest the possible development and clinical use of specific antagonists in TNBC treatment. Furthermore, the role of ERβ might be regarded in the context of the androgen receptor (AR) expression, which represents another key marker in TNBC. The relationship between AR and ERβ as well as the ability to modulate the receptor-mediated effects through agonists/antagonists represent a challenge to develop more appropriate therapies in clinical management of TNBC patients. In this review, we will discuss the most recent data in the field. Therapeutic implications of these findings are also presented in the light of the discovery of specific ERβ modulators.

Sign in / Sign up

Export Citation Format

Share Document